title: Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study.
abstract: BACKGROUND
  On the basis of the presence of beta2-receptors within the sympathetic nervous system, beta2-stimulation may increase cardiac sympathetic outflow. We addressed the hypothesis that sympathoexcitatory beta2-receptors are present in the human left ventricle.
  
  
  RESULTS
  The beta2-agonist salbutamol was infused into the left coronary artery in 3 groups of patients: group 1 (n=9, no beta-blocker therapy), group 2 (n=7, beta1-selective blockade with atenolol), and group 3 (n=6, nonselective beta-blockade with nadolol). Left ventricular +dP/dt in response to increasing concentrations of salbutamol was measured in all groups, and cardiac norepinephrine spillover was measured in group 1. There were no systemic hemodynamic changes in any group. Salbutamol resulted in a 44+/-6% increase in +dP/dt in group 1, a 25+/-6% increase in group 2 (P<0.05 versus group 1), and no increase in group 3. Salbutamol also resulted in a 124+/-37% increase in cardiac norepinephrine spillover in group 1 (P<0.05).
  
  
  CONCLUSIONS
  Evidence that salbutamol increased norepinephrine release from cardiac sympathetic nerves was provided by the observations that atenolol suppressed the salbutamol inotropic response, demonstrating that this response was mediated in part by beta1-receptors and that salbutamol also resulted in an increase in cardiac norepinephrine spillover. This result provides in vivo evidence, in humans, for the role of sympathoexcitatory cardiac beta2-receptors.
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000494:pharmacology*; D001262:Atenolol / Q000494:pharmacology; D006328:Cardiac Catheterization; D002637:Chest Pain / Q000175:diagnosis; D003327:Coronary Disease / Q000503:physiopathology*; D003331:Coronary Vessels; D005260:Female; D006321:Heart / Q000187:drug effects / Q000502:physiology; D006352:Heart Ventricles / Q000294:innervation; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D009248:Nadolol / Q000008:administration & dosage / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects*; D013566:Sympathomimetics / Q000008:administration & dosage / Q000494:pharmacology*